Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jose Mendoza

Internal Medicine Avon, OH Medical Doctor

NPI 1578533659 CMS profile 693226

1813 Nagel Rd Ste 500, Avon, OH 44011

Open in the dashboard

General payments

$16,481

957 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jose Mendoza of Avon, OH is reported in the CMS Open Payments database as having received $16,481 across 957 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $389 3
2024 General $318 5
2023 General $2,797 131
2022 General $3,573 213
2021 General $3,069 183
2020 General $2,593 174
2019 General $3,742 248

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jose Mendoza
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Jose Mendoza were reported at $389. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Jose Mendoza Internal Medicine median Middle half National median
2019 $3,742 $159 $48–$570 $163
2020 $2,593 $119 $33–$402 $114
2021 $3,069 $135 $37–$521 $132
2022 $3,573 $141 $42–$496 $149
2023 $2,797 $149 $45–$519 $160
2024 $318 $154 $47–$537 $164
2025 $389 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,289 117 payments
  2. AstraZeneca Pharmaceuticals LP $1,644 61 payments
  3. Pfizer Inc. $1,565 108 payments
  4. GlaxoSmithKline, LLC. $1,156 66 payments
  5. Novo Nordisk Inc $1,092 73 payments
  6. Amgen Inc. $882 38 payments
  7. Lilly USA, LLC $703 48 payments
  8. Teva Pharmaceuticals USA, Inc. $584 42 payments
  9. Allergan Inc. $562 36 payments
  10. Novartis Pharmaceuticals Corporation $552 45 payments
  11. Other $5,452 323 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,171 947 payments
  2. Education $310 10 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $977 45 payments
  2. UBRELVY $925 46 payments
  3. NURTEC ODT $810 31 payments
  4. TRELEGY ELLIPTA $762 51 payments
  5. Ozempic $742 59 payments
  6. COLOGUARD $722 52 payments
  7. EUCRISA $654 45 payments
  8. VRAYLAR $619 26 payments
  9. AIMOVIG $538 28 payments
  10. BREZTRI $478 13 payments
  11. Other $13,789 941 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 211 drugs

Part D claims

17,788

Median for Internal Medicine: 777

Drug cost

$1,062,381

Median for Internal Medicine: $73,373

Branded share of claims

21.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 155 $206,191
Jardiance Empagliflozin Brand 125 $128,452
Trulicity Dulaglutide Brand 74 $82,955
Eliquis Apixaban Brand 78 $76,920
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 99 $72,683
Januvia Sitagliptin Phosphate Brand 52 $53,036
Mounjaro Tirzepatide Brand 29 $37,840
Linzess Linaclotide Brand 45 $28,884
Xarelto Rivaroxaban Brand 43 $22,214
Kerendia Finerenone Brand 16 $16,641

The 10 drugs with the highest cost, of 211 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$54,270

Of which drugs: $3,280

Medicare patients

255

Average age 72

Services billed

978

116 women, 139 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 42%
Diabetes 32%
Ischemic heart disease 26%
Chronic kidney disease 22%
COPD 19%
Atrial fibrillation 18%
Depression 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 21 21 $1,718

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $125
$125 — —
Wegovy
  • Novo Nordisk Inc $118
$118 — —
SARCLISA
  • GENZYME CORPORATION $28
$28 — —
Padcev
  • PFIZER INC. $24
$24 — —
NURTEC ODT
  • PFIZER INC. $12
$12 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

957 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record